JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2013, 62(3):127-131

A study of a new co-processed dry binder based on spray-dried lactose and microcrystalline cellulose

Jitka Mužíková*, Pavla Šináglová
Department of Pharmaceutical Technology, Faculty of Pharmacy Charles University in Prague, Hradec Králové

The paper studies the compressibility and disintegration time of tablets from the co-processed dry binder DisintequikTM MCC in combination with two lubricants at two concentrations in dependence on compression force. It also compares identical parameters in the physical mixtures of the spray-dried lactose Flowlac® 100 and the microcrystalline cellulose Microcel® MC-102 in the ratios of 9 : 1, 8 : 2 and 7 : 3, again in combination with two lubricants of two concentrations at one compression force. The lubricants employed are magnesium stearate and poloxamer 407 in concentrations of 1% and 2%. Compressibility is evaluated by means of energy balance of compression and tensile strength of tablets. DisintequikTM MCC shows higher values of total energy of compression due to higher values of the energy accumulated by the tablet, higher plasticity, higher strength and a longer disintegration time of tablets than the physical mixture of spray-dried lactose and microcrystalline cellulose of a corresponding content.

Keywords: DisintequikTM MCC; magnesium stearate; poloxamer 407; energy profile of compression; tensile strength of tablets; disintegration time of tablets
Grants and funding:

The study was supported by the firm Kerry Bio-Science, Meggle-Pharma and Blanver, which supplied the samples of the dry binders tested.

Received: March 13, 2013; Accepted: March 26, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mužíková J, Šináglová P. A study of a new co-processed dry binder based on spray-dried lactose and microcrystalline cellulose. Čes. slov. farm. 2013;62(3):127-131.
Download citation

References

  1. Nachaegari S. K., Bansal A. K. Coprocessed excipients for solid dosage forms. Pharm Technol 2004; 28, 52-64.
  2. Saha S., Shahiwala A. F. Multifunctional coprocessed excipients for improved tableting performance. Expert Opin Drug Deliv. 2009; 6, 197-208. Go to original source... Go to PubMed...
  3. Bolhuis G. K., Armstrong N. A. Excipients for direct compaction - an update. Pharm Dev Technol. 2006; 11, 111-124. Go to original source... Go to PubMed...
  4. Gohel M. C., Jogani P. D. A review of co-processed directly compressible excipients. J Pharm Pharmaceut Sci 2005; 8, 76-93.
  5. Kerry: Self lubricating excipients. Firm. lit. 2012 http://www.sheffieldbioscience.com/LubriTose/
  6. JRS Pharma: Prosolv® Easytab. Firm. Lit. 2010 http://www.jrspharma.de/Pharma/wEnglisch/produktinfo/productinfo_prosolv_easytab.shtml
  7. Kerry: Disintequik MCC. Firm. Lit. 2012 http://www.sheffieldbioscience.com/disintequik_mcc/
  8. Ragnarsson G. Force-displacement and network measurements. In: Alderborn G., Nystrőm Ch. eds. Pharmaceutical Powder Compaction Technology New York: Marcel Dekker, Inc. 1996; 77-97. Go to original source...
  9. Fell J. T., Newton, J. M. Determination of tablet strength by diametral-compression test. J. Pharm. Sci. 1970; 59, 688-691. Go to original source... Go to PubMed...
  10. Czech Pharmacopoeia 2009 - Supplement 2010. Praha: Grada Publishing 2010; 4082.
  11. Belousov V. A. K voprosu o vybore optimalnikh davlenii pressovania pri tabletirovanii lekarstvennykh poroshkov. Khim. Farm. Zh. 1976; 10, 105-111.
  12. Picker-Freyer K. M. Tablet production systems. In: Gad S. C. (ed.) Pharmaceutical Manufacturing handbook production and processes. New Jersey: John Wiley and Sons, Inc. 2008; 1053-1098. Go to original source...
  13. Bolhuis G. K., Hőlzer A. W. Lubrication Issues in direct compaction. In: Alderborn G., Nyström Ch. (eds.) Pharmaceutical powder compaction technology. London: Informa Healthcare, 2011; 205-234.
  14. Dumortier G., Grossiord J. L., Agnely F., Chaumeil J. C. A review of poloxamer 407. Pharmaceutical and Pharmacological Characteristics. Pharm. Research 2006; 23, 2709-2728. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.